Copyright Reports & Markets. All rights reserved.

Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Paclitaxel
      • 1.4.3 Docetaxel
      • 1.4.4 Liposome Paclitaxel
      • 1.4.5 Protein-bound Paclitaxel
    • 1.5 Market by Application
      • 1.5.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Application (2014-2025)
      • 1.5.2 Ovarian Cancer
      • 1.5.3 Breast Cancer
      • 1.5.4 Cervical Cancer
      • 1.5.5 Pancreatic Cancer
      • 1.5.6 Non-small Cell Lung Cancer
      • 1.5.7 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size
    • 2.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Growth Trends by Regions
      • 2.2.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Regions (2014-2025)
      • 2.2.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by by Players
      • 3.1.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by by Players (2014-2019)
      • 3.1.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players Head office and Area Served
    • 3.3 Key Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Product/Solution/Service
    • 3.4 Date of Enter into Paclitaxel and Its Analogue in Anticarcinoma Drugs Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type (2014-2019)
    • 4.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2014-2019)
    • 5.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in United States
    • 5.3 United States Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type
    • 5.4 United States Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application

    6 Europe

    • 6.1 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2014-2019)
    • 6.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Europe
    • 6.3 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type
    • 6.4 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application

    7 China

    • 7.1 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2014-2019)
    • 7.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in China
    • 7.3 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type
    • 7.4 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application

    8 Japan

    • 8.1 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2014-2019)
    • 8.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Japan
    • 8.3 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type
    • 8.4 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2014-2019)
    • 9.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Southeast Asia
    • 9.3 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type
    • 9.4 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application

    10 India

    • 10.1 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2014-2019)
    • 10.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in India
    • 10.3 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type
    • 10.4 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (2014-2019)
    • 11.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Key Players in Central & South America
    • 11.3 Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Type
    • 11.4 Central & South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Application

    12 International Players Profiles

    • 12.1 Bristol-Myers Squibb
      • 12.1.1 Bristol-Myers Squibb Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.1.4 Bristol-Myers Squibb Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.1.5 Bristol-Myers Squibb Recent Development
    • 12.2 Celgene Corporation
      • 12.2.1 Celgene Corporation Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.2.4 Celgene Corporation Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.2.5 Celgene Corporation Recent Development
    • 12.3 Hospira
      • 12.3.1 Hospira Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.3.4 Hospira Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.3.5 Hospira Recent Development
    • 12.4 Biological E.
      • 12.4.1 Biological E. Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.4.4 Biological E. Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.4.5 Biological E. Recent Development
    • 12.5 Taj Accura
      • 12.5.1 Taj Accura Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.5.4 Taj Accura Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.5.5 Taj Accura Recent Development
    • 12.6 Khandelwal Laboratories
      • 12.6.1 Khandelwal Laboratories Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.6.4 Khandelwal Laboratories Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.6.5 Khandelwal Laboratories Recent Development
    • 12.7 Luye Pharma
      • 12.7.1 Luye Pharma Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.7.4 Luye Pharma Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.7.5 Luye Pharma Recent Development
    • 12.8 Beijing Youcare
      • 12.8.1 Beijing Youcare Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.8.4 Beijing Youcare Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.8.5 Beijing Youcare Recent Development
    • 12.9 Beijing Union
      • 12.9.1 Beijing Union Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.9.4 Beijing Union Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.9.5 Beijing Union Recent Development
    • 12.10 Haiyao
      • 12.10.1 Haiyao Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Paclitaxel and Its Analogue in Anticarcinoma Drugs Introduction
      • 12.10.4 Haiyao Revenue in Paclitaxel and Its Analogue in Anticarcinoma Drugs Business (2014-2019)
      • 12.10.5 Haiyao Recent Development
    • 12.11 Chuntch
    • 12.12 Hengrui Medicine
    • 12.13 Sanofi
    • 12.14 Qilu Pharma
    • 12.15 Shenzhen Main Luck Pharma
    • 12.16 Jiangsu Aosaikang Pharma
    • 12.17 CSPC Pharmaceutical
    • 12.18 Aosaikang Pharm

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Paclitaxel and Its Analogue in Anticarcinoma Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Paclitaxel and Its Analogue in Anticarcinoma Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Paclitaxel and Its Analogue in Anticarcinoma Drugs development in United States, Europe and China.

      The key players covered in this study
      Bristol-Myers Squibb
      Celgene Corporation
      Hospira
      Biological E.
      Taj Accura
      Khandelwal Laboratories
      Luye Pharma
      Beijing Youcare
      Beijing Union
      Haiyao
      Chuntch
      Hengrui Medicine
      Sanofi
      Qilu Pharma
      Shenzhen Main Luck Pharma
      Jiangsu Aosaikang Pharma
      CSPC Pharmaceutical
      Aosaikang Pharm

      Market segment by Type, the product can be split into
      Paclitaxel
      Docetaxel
      Liposome Paclitaxel
      Protein-bound Paclitaxel

      Market segment by Application, split into
      Ovarian Cancer
      Breast Cancer
      Cervical Cancer
      Pancreatic Cancer
      Non-small Cell Lung Cancer
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Paclitaxel and Its Analogue in Anticarcinoma Drugs status, future forecast, growth opportunity, key market and key players.
      To present the Paclitaxel and Its Analogue in Anticarcinoma Drugs development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Paclitaxel and Its Analogue in Anticarcinoma Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now